CD274 and non-small cell lung carcinoma: As immune checkpoint inhibitors (ICIs) have been recently used as a new strategy for treatment in NSCLC, it is necessary to identify biomarkers that are able to predict the efficacy to anti‐PD‐1/PD‐L1 treatment.